leisure time -WSS

leisure time

author：hotspot 2025-10-02 21:00:41 - browse：15

Doctor Monica Bertagnolli, a white woman with short hair and bangs, sits at a hearing behind her name tag — coverage from STAT — National Institutes of Health Director Monica Bertagnolli testifies during her Senate HELP Committee confirmation hearing on Oct. 18 in Washington. Kevin Dietsch/Getty Images

WASHINGTON — The new National Institutes of Health director, Monica Bertagnolli, said it’s a “failure” that enrollment in government-funded clinical trials has lagged behind those funded by the pharmaceutical industry.

“If you just look at the number of patients who go on government-funded trials, it’s been completely flat over the last decade,” she said at a meeting of the advocacy group Friends of Cancer Research. “If you go and look at the number of people who go on pharma-sponsored trials, it’s just this commitment and this increase.”

A Johns Hopkins University study published in 2015 showed that the pharmaceutical industry funds six times more clinical trials than the government. Industry-sponsored trials increased 43% from 2006 to 2014, while newly registered NIH-funded trials decreased 24% over the same period.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： First U.S. drug developed to treat liver disease MASH is approved

WSS

RaDonda Vaught links Vanderbilt hospital issues to patient death

AstraZeneca bets AAV gene therapy will still deliver the goods

AstraZeneca challenges Medicare drug negotiation program

Radiation, mainstay of cancer treatment, begins a fade

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

How to make AI work for medicine

entertainment

leisure time

Wikipedia

Drug repurposing or repositioning? The language matters

As pharma fights Medicare drug negotiation, hospitals, docs silent

After affirmative action ruling, medical educators look to 'holistic review'

Medicare explains how it will choose drugs for negotiation

Apple is now the first public company to be valued at $3 trillion

RaDonda Vaught links Vanderbilt hospital issues to patient death

Apple is now the first public company to be valued at $3 trillion

AstraZeneca bets AAV gene therapy will still deliver the goods

Hepatitis C has a cure — but many Americans still lack access to it

John Green on his newest strategy for fighting tuberculosis

leisure time

Neuroscience startup Neumora files for IPO

How many hemophilia patients actually want gene therapy?

Radiation, mainstay of cancer treatment, begins a fade

Pushing for an NIH office for post

CDC advisory panel says seniors 'may' get RSV vaccine

Ebola: Gilead Sciences antiviral shows promise as new treatment

knowledge

hotspot

hotspot

hotspot